SCHEMBL2861659

SCHEMBL2861659

CSc1ncc(-c2ccc(O)c(F)c2)c(=O)n1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
AR P10275 1/20 0.39
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
HSD17B1 P14061 1/20 0.37
DAO P14920 1/20 0.37
ESR2 Q92731 2/20 0.36
MIF P14174 2/20 0.36
HSD17B14 Q9BPX1 1/20 0.36
KDM4E B2RXH2 3/20 0.35
HSD17B10 Q99714 3/20 0.35
LMNA P02545 2/20 0.35
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP17A1 P05093 1/20 0.35
CYP19A1 P11511 1/20 0.35
ESR1 P03372 2/20 0.35
RIPK1 Q13546 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382384 0.82 KDM4E (0.47) ALDH1A1ARKDM4EHSD17B10HPGD
SCHEMBL15426773 0.75 MET (0.63) FGFR2
SCHEMBL2379712 0.75 MET (0.58) MIFCYP11B1CYP11B2CYP3A4CYP17A1
SCHEMBL2288757 0.75 MET (0.58) ALDH1A1FGFR2MAPK1USP2CYP1A2
SCHEMBL2855704 0.75 MET (0.58) ARFGFR1FGFR2USP2CYP1A2
SCHEMBL3915728 0.75 MET (0.42) ALDH1A1MIFHSD17B10CYP3A4HPGD
SCHEMBL3912607 0.74 MIF (0.37) ARESR2MIFKDM4EHSD17B10
SCHEMBL3117756 0.74 KDM1A (0.40) ARFGFR1FGFR2HSD17B1ESR2
SCHEMBL3111973 0.72 MIF (0.38) HSD17B1ESR2MIFESR1
SCHEMBL3117761 0.72 MET (0.39) MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1827434-B1 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC (US) 2014-01-15 EP disclosed
US-7652009-B2 Substituted heterocycles and methods of use AMGEM INC. (US) 2010-01-26 US disclosed
EP-1827434-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER Amgen Inc. (US) 2007-09-05 EP disclosed
US-20060252777-A1 Substituted heterocycles and methods of use AMGEN INC. (US) 2006-11-09 US disclosed
WO-2006060318-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252777-A1 Substituted heterocycles and methods of use HGF, HGFAC, MET ALDH1A1 95/4885AR 1895/4885FGFR1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.